Lundbeck delivers strong growth

H. Lundbeck A/SH. Lundbeck A/S (Lundbeck) reports first quarter revenue of DKK 3,849 million growing 15% in constant exchange rates compared to the first quarter results of 2009. Profit from operations was DKK 1,254 million, an increase of 32% compared to the same period last year. The EBIT margin for the quarter increased to 32.6% up from 28.6% in 2009.

  • Cipralex® revenue was DKK 1,454 million, an increase of 5% compared to last year. Cipralex® revenue in Europe was up 10% for the quarter.
  • Ebixa® and Azilect® continue to show solid growth, increasing 17% and 46% respectively.
  • US sales were DKK 1,044 million, an increase of 53%. Lexapro® revenue increased 9%.
  • Sabril® revenue for the quarter was DKK 34 million.
  • Operating profit before depreciation and amortisation (EBITDA) was DKK 1,478 million corresponding to an EBITDA margin of 38.4% compared to an EBITDA margin of 32.6% in the first quarter of 2009.
  • Financial guidance for the full year is maintained. Lundbeck expects revenue of DKK 14.3-14.8 billion, EBITDA of DKK 3.9-4.3 billion and EBIT of DKK 3.0-3.4 billion for 2010.

In connection with the first quarter report, Lundbeck's President and CEO Ulf Wiinberg said: "The first quarter of 2010 has been very strong for Lundbeck, and revenue and profits continue to show firm growth. All key products are delivering good results and Cipralex® continues to show solid growth across Europe and in most of our International Markets. With the results for the quarter we are off to a good start to deliver on our financial guidance."

About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 5,900 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with CNS disorders. In 2009, the company's revenue was DKK 13.7 billion (approximately EUR 1.8 billion or USD 2.6 billion). For more information, please visit www.lundbeck.com.

Most Popular Now

Roche launches imCORE, a global network of cancer …

Roche (SIX: RO, ROG; OTCQX: RHHBY) has launched the global cancer immunotherapy Centers of Research Excellence (imCORE™) Network. This network brings together many of the...

Read more

15th Annual eyeforpharma Philadelphia 2017

20 - 21 April 2017, Philadelphia, USA. It's eyeforpharma Philadelphia's 15th year; already the largest, most senior and most influential forum for commercial pharma exec...

Read more

Merck wins R&D 100 Award for top invention

Merck, a leading science and technology company, received a prestigious R&D 100 Award for its Sanger Arrayed Lentiviral CRISPR Libraries - the first of its kind CRISPR li...

Read more

Benzodiazepine and related drug use increases hip …

The use of benzodiazepines and related drugs increases the risk of hip fracture by 43% in persons with Alzheimer's disease, according to a new study from the University o...

Read more

Among antidementia drugs, memantine is associated …

A recent study from the University of Eastern Finland shows that among users of antidementia drugs, persons using memantine have the highest risk of pneumonia. The use of...

Read more

World of viruses uncovered

A groundbreaking study of the virosphere of the most populous animals - those without backbones such as insects, spiders and worms and that live around our houses - has u...

Read more

Boehringer Ingelheim and China Southeast Universit…

Boehringer Ingelheim and China Southeast University Institute of Life Sciences have announced the start of a joint research project to develop new treatment approaches fo...

Read more

Smart patch releases blood thinners as needed

An interdisciplinary team of researchers has developed a smart patch designed to monitor a patient's blood and release blood-thinning drugs as needed to prevent the occur...

Read more

Novartis acquires Selexys Pharmaceuticals Corporat…

Novartis today announced it has acquired Selexys Pharmaceuticals Corporation, a company specializing in development of therapeutics in certain hematologic and inflammator...

Read more

Novo Nordisk expands programme to reach 20,000 chi…

Today, Novo Nordisk announced a four-year extension of its Changing Diabetes® in Children programme which provides access to diabetes care and free insulin to children wi...

Read more

IBM and Pfizer to accelerate immuno-oncology resea…

IBM (NYSE: IBM) Watson Health and Pfizer Inc. (NYSE: PFE) have announced a collaboration that will utilize IBM Watson for Drug Discovery to help accelerate Pfizer's resea...

Read more

Greater efforts are needed to encourage patients t…

In a review of published studies addressing patients' perceptions and factors influencing their reporting of adverse drug reactions, most patients were not aware of repor...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]